Breadcrumb

[A17-05] Ceritinib (lung cancer) - Addendum to Commission A16-62

Overview

Overview

Commission: Commission awarded on 2017-02-06 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A16-62  [PDF, 706 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A16-62] Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-03-16 Addendum to Commission A16-62 706 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2017-03-16 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close